JP2017525758A5 - - Google Patents

Info

Publication number

JP2017525758A5

JP2017525758A5 JP2017525516A JP2017525516A JP2017525758A5 JP 2017525758 A5 JP2017525758 A5 JP 2017525758A5 JP 2017525516 A JP2017525516 A JP 2017525516A JP 2017525516 A JP2017525516 A JP 2017525516A JP 2017525758 A5 JP2017525758 A5 JP 2017525758A5

Authority

JP

Japan

Prior art keywords

pharmaceutically acceptable

ophthalmic

composition according

ophthalmic composition

rifampicin

Prior art date

2015-07-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims 13
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
• 229930189077 Rifamycin Natural products 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 239000003937 drug carrier Substances 0.000 claims 3
• 238000009472 formulation Methods 0.000 claims 3
• 229960001225 rifampicin Drugs 0.000 claims 3
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 3
• 229960003292 rifamycin Drugs 0.000 claims 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
• 208000022873 Ocular disease Diseases 0.000 claims 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
• ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 2
• 239000000654 additive Substances 0.000 claims 2
• 230000000996 additive effect Effects 0.000 claims 2
• 206010064930 age-related macular degeneration Diseases 0.000 claims 2
• 208000035475 disorder Diseases 0.000 claims 2
• 239000003889 eye drop Substances 0.000 claims 2
• 208000002780 macular degeneration Diseases 0.000 claims 2
• 229960000885 rifabutin Drugs 0.000 claims 2
• -1 rifamycin compound Chemical class 0.000 claims 2
• 229960002599 rifapentine Drugs 0.000 claims 2
• WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims 2
• NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 2
• 229960003040 rifaximin Drugs 0.000 claims 2
• 230000000699 topical effect Effects 0.000 claims 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
• 229930195725 Mannitol Natural products 0.000 claims 1
• 206010029113 Neovascularisation Diseases 0.000 claims 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
• 239000003242 anti bacterial agent Substances 0.000 claims 1
• 239000003963 antioxidant agent Substances 0.000 claims 1
• 230000003078 antioxidant effect Effects 0.000 claims 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
• 208000029028 brain injury Diseases 0.000 claims 1
• 239000000337 buffer salt Substances 0.000 claims 1
• 239000012876 carrier material Substances 0.000 claims 1
• 230000005779 cell damage Effects 0.000 claims 1
• 208000037887 cell injury Diseases 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 239000008121 dextrose Substances 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 208000030533 eye disease Diseases 0.000 claims 1
• 235000011187 glycerol Nutrition 0.000 claims 1
• 239000000594 mannitol Substances 0.000 claims 1
• 235000010355 mannitol Nutrition 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000006174 pH buffer Substances 0.000 claims 1
• 239000001103 potassium chloride Substances 0.000 claims 1
• 235000011164 potassium chloride Nutrition 0.000 claims 1
• 239000003755 preservative agent Substances 0.000 claims 1
• 230000002335 preservative effect Effects 0.000 claims 1
• 210000003994 retinal ganglion cell Anatomy 0.000 claims 1
• HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 1
• 150000003839 salts Chemical class 0.000 claims 1
• 239000011780 sodium chloride Substances 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1
• 238000010254 subcutaneous injection Methods 0.000 claims 1
• 239000007929 subcutaneous injection Substances 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 239000004094 surface-active agent Substances 0.000 claims 1
• 239000008181 tonicity modifier Substances 0.000 claims 1